愛博醫療(688050.SH)：上半年淨利同比增2.3%至3753.87萬元
格隆匯 8 月 25日丨愛博醫療(688050.SH)披露半年報，2020年1-6月公司實現營業收入1.04億元,較上年同期增長9.39%。其中人工晶狀體收入9001.71萬元，角膜塑形鏡收入1083.49萬元，其他產品及服務收入272.75萬元。2020年1-6月公司實現歸屬於上市公司股東的淨利潤3753.87萬元，較上年同期增長2.30%，其中2020年1季度同比下降80.10%，2020年2季度同比增長74.70%。2020年1-6月公司實現歸屬於上市公司股東扣除非經常性損益後的淨利潤為3618.44萬元，較上年同期增長2.86%，其中2020年1季度同比下降82.08%，2020年2季度同比增長78.14%。
2020年1季度受新冠肺炎疫情以及春節假期影響，終端醫療機構的白內障手術和角膜塑形鏡驗配業務大幅減少，營業收入同比下降39.15%。2020年2季度隨着國內疫情好轉，市場逐漸恢復，營業收入同比增長49.90%,其中：人工晶狀體銷量同比增長33.02%，人工晶狀體銷售收入同比增長39.38%；同時角膜塑形鏡產品2019年3月取得產品註冊證以來，經過一年左右的市場推廣，市場銷量快速提升，2020年2季度實現收入791.61萬元，較上年同期增長575.42%。2020年上半年患者配戴片銷量為16181片，其中1季度銷量為4217片，2季度銷量為11964片。
2020年1-6月公司研發投入1,405.56萬元，較上年同期增長22.86%。公司在疫情期間通過多方舉措盡力保障研發進度。報告期內公司在境內獲批7項發明專利，5項實用新型專利及1項外觀設計專利，同時境外在美國獲批1項發明專利。產品註冊方面，境內預裝式人工晶狀體A1UL於2020年5月取得國內醫療器械產品註冊證。境外方面，2020年2月取得泰國人工晶狀體AQBHL產品註冊證書，2020年3月取得韓國人工晶狀體A1UL產品註冊證書，2020年5月取得泰國人工晶狀體A1-UV、一次性植入系統DIS產品註冊證。
報告期內，公司持續加強市場拓展，尤其角膜塑形鏡的銷售團隊建設，持續增加一線銷售人員及技術培訓人員，保障公司產品使用效果和用量的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
